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A commentary on
Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease
by Qamhawi Z, Towey D, Shah B, Pagano G, Seibyl J, Marek K, et al. Brain (2015) 138(Pt 10):2964–73.
doi: 10.1093/brain/awv215
Growing and clinical evidence supports the conclusion that Parkinson’s Disease (PD) is a complex
multisystem disorder not exclusively affecting the dopaminergic circuits. In fact, the dopaminergic
neuronal loss does not cover all the clinical aspects of PD. Therefore, different non-dopaminergic
neurotransmitter systems have been invoked as playing a role in the PD clinical picture. Principally,
the inefficiency of serotonergic circuitry has been demonstrated in PD animal models, as well as in
post-mortem and in vivo human studies.
In the recent article published in Brain, Zahi Qamhawi and colleagues interrogated 123I-FP-CIT
single-photon emission computed tomography documenting raphe serotonergic dysfunction in a
large group of early PD patients compared to a subset of possible PD patients without evidence
of dopaminergic deficit (SWEDD) and a population of healthy controls (1). This paper combined
an accurate clinical evaluation with a sophisticated neuroimaging protocol and documented in
PD patients a mean raphe serotonin (5-HT) transporter availability significantly lower than both
SWEDD patients and controls. These findings, achieved in a large cohort of PD patients, enforced
previous autoptic examinations documenting serotonergic neurons loss due to Lewy body pathology
in the raphe nuclei of PDpatients (2). Accordingly, neuroimaging studies have shown the progressive
5-HT transporter availability reduction in the raphe nuclei as PD pathology progresses (3–5).
It is well accepted that concentration of 5-HT and its metabolite 5-hydroxyindolacetic acid (5-
HIAA) in CSF reflects the serotonergic metabolism and turnover in the CNS (6, 7). We performed
a case-control study investigating CSF levels of 5-HT and 5-HIAA in a cohort of PD patients,
after a 3-day dopaminergic therapy withdrawal and in absence of serotonergic agents (8). We
demonstrated the significant reduction of CSF 5-HT and 5-HIAA concentrations in PD patients
compared to controls. We also found the significant reduction of CSF 5-HT and 5-HIAA in the PD
population with respect to Alzheimer’s Disease patients (8), thus highlighting that the impairment
of serotonergic system could represent a specific effect of synuclein-mediated neurodegeneration
(8). As a matter of fact, novel experimental studies in alpha-synuclein (α-syn) mouse model of PD
showed the impairment of serotonergic system owing to the intracellular accumulation of α-syn in
serotonergic neurons coupled with the reduction of 5-HT levels in lower brainstem (9).
Based on the clinical presentation, Qamhawi and collegues divided PD patients into two sub-
groups corresponding to patients with and without resting tremor. Remarkably, patients with
tremor had lower mean raphe 5-HT transporter availability than patients unaffected by tremor.
Frontiers in Neurology | www.frontiersin.org December 2015 | Volume 6 | Article 2611
Liguori et al. Serotonergic System Inefficiency in PD
Since tremor amplitude, constancy, and severity negatively cor-
related with raphe 5-HT transporter availability in the whole
PD cohort, authors suggested that the serotonergic system inef-
ficiency could be responsible for parkinsonian tremor. This find-
ing was consistent with previous studies detecting an association
between 5-HT receptor availability in the raphe nuclei and severity
of parkinsonian tremor (10). However, in our CSF study, we found
no differences in CSF 5-HT and 5-HIAA levels between tremor
dominant and non-tremor dominant patients. This discrepancy
could be ascribed to the fact that Qamhawi and collegues studied
de novo early PD patients, whereas we investigated patients with
higher Hoehn and Yahr stage and greater motor disability at the
Unified PD Rating Scale-motor section. It could be of interest
to evaluate in follow-up studies how the serotonergic transmis-
sion damage may influence PD motor symptoms along with the
progression of the disease. Concurrently, the reliability of the
proposed difference in raphe 5-HT transporter availability found
by Qamhawi and coworkers in early PD patients should be also
analyzed in more advanced PD patients.
Remarkably, Qamhawi and coauthors documented that raphe
5-HT transporter availability did not correlatewith PDnon-motor
symptoms, such as fatigue, depression, and sleep-wake cycle dis-
turbances. In agreement with this finding, we did not identify
mutual interplays linking CSF 5-HT and 5-HIAA concentrations
to depression, apathy, and sleep disturbances. Although our report
sustained Qamhawi and coworkers results, literature proposes
controversial data regarding the involvement of serotonergic path-
ways breakage in the pathophysiology of PD non-motor symp-
toms (11), thus requiring further investigations.
All considering, we suppose that the reduced 5-HT transporter
availability, as shown by Qamhawi and collegues, and the 5-
HT synthesis, metabolism, and turnover impairment, resulting in
reduced CSF levels of 5-HT and 5-HIAA (8) may both contribute
to the serotonergic transmission dysfunction evident in PD.
Hence, serotonin circuitry inefficiency could represent the
fitting partner of the dopaminergic deficit in PD.
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